Table 1.
Baseline characteristics across black, Hispanic, and Asian patients (integrated analysis of DEFINE and CONFIRM)
| Characteristica | Black patients | Hispanic patients | Asian patients | ITT population | ||||
|---|---|---|---|---|---|---|---|---|
| Placebo (n = 19) | DMFb (n = 10) | Placebo (n = 23) | DMFb (n = 31) | Placebo (n = 70) | DMFb (n = 66) | Placebo (n = 771) | DMFb (n = 769) | |
| Age, years | 37.3 (10.2) | 39.0 (8.7) | 32.1 (8.2) | 31.7 (10.3) | 34.8 (9.8) | 34.0 (9.1) | 37.7 (9.2) | 37.9 (9.2) |
| Female, n (%) | 14 (73.7) | 7 (70.0) | 14 (60.9) | 21 (67.7) | 38 (54.3) | 48 (72.7) | 557 (72.0) | 541 (70) |
| Time since first MS symptoms, years | 7.3 (8.2) | 5.6 (6.4) | 5.3 (4.9) | 4.5 (4.8) | 6.0 (4.6) | 6.2 (4.9) | 8.1 (6.5) | 8.3 (6.8) |
| Time since first MS diagnosis, years | 4.3 (7.4) | 3.1 (3.8) | 4.0 (4.6) | 3.3 (5.0) | 4.3 (4.1) | 4.0 (3.3) | 5.3 (5.5) | 5.3 (5.3) |
| Prior approved MS treatmentc, n (%) | 11 (57.9) | 4 (40.0) | 7 (30.4) | 10 (32.3) | 6 (8.6) | 5 (7.6) | 95 (12) | 50 (7) |
| Number of relapses in prior year | 1.4 (0.6) | 1.8 (0.9) | 1.5 (1.5) | 1.4 (0.6) | 1.6 (0.9) | 1.4 (0.9) | 1.3 (0.7) | 1.3 (0.7) |
| EDSS score | 2.1 (1.0) | 1.9 (1.6) | 2.3 (1.4) | 2.0 (1.1) | 2.8 (1.1) | 3.3 (1.1) | 2.5 (1.2) | 2.5 (1.3) |
EDSS Expanded Disability Status Scale, MS multiple sclerosis, SD standard deviation
aValues are mean ± SD unless otherwise stated
bDMF denotes delayed-release dimethyl fumarate (DMF; also known as gastro-resistant DMF) at the approved dosage, 240 mg BID
cApproved medications for multiple sclerosis included glatiramer acetate, interferon (beta-1a and beta-1b), and natalizumab. Patients may have received more than one prior medication for multiple sclerosis. Patients may also have received other, nonapproved therapies for multiple sclerosis